109 results about "Stromal tumor" patented technology

The present invention relates to an in vitro method for diagnosing and / or monitoring in a subject a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising detecting and / or analyzing in a test sample derived from the subject one or more mutations at the DNA level in any one or both of the marker genes cKIT (GenBank acc. no. NM_000222.2) and PDGFRA (GenBank acc. no. NM_006206.4), wherein the DNA is circulating DNA, and wherein the presence of any one of the mutations detected in the test sample is indicative of a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor in the subject. The present invention is also directed to a corresponding kit-of-parts for diagnosing and / or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising means for detecting and / or analyzing one or more mutations as defined herein, as well as to the use of one or more mutations as defined herein as a panel of molecular markers for diagnosing and / or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

The present invention provides novel phthalazinone compounds and isomer thereof, pharmaceutically acceptable salts, solvates, chemically protected forms, and prodrugs; which can be used as PARP inhibitor and pharmaceutical compositions containing the novel phthalazinone compounds; wherein A, R1 and X are defined as shown. The medicine is used for the treatment of: vascular diseases, neurotoxicity, or diseases improved through the inhibition of PARP activity; or used as adjuvants for the treatment of cancers, or used for enhancing the therapeutic effect of radiation or chemotherapeutic agents on tumor cells, wherein the cancers includes breast cancer, ovarian cancer, colon cancer, melanoma, lung cancer, gastrointestinal stromal tumor, brain cancer, cervical cancer, pancreatic cancer, prostate cancer, gastric cancer, chronic myeloid leukocytes hypercytosis, liver canser, lymphoma, peritoneal cancer, soft tissue sarcoma, neuroendocrine tumors, advanced solid tumors, and glioblastoma.

The present invention relates to methods and compositions concerning resistance to a drug for cancer comprising aberrant KIT signal, such as aberrant KIT sequence or expression. In a specific embodiment, the cancer is also initially responsive to imatinib therapy, such as in gastrointestinal stromal tumors (GISTs). In particular embodiments, a mutation in a KIT polynucleotide confers resistance to imatinib treatment, and in specific embodiments the exemplary mutation is at 1982T→C. Thus, the invention provides a means to adjust for or circumvent the resistance to imatinib drug treatment.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The invention discloses a gastrointestinal stromal tumor pathological diagnosis support system and method based on big-data deep learning, and the system comprises an image data obtaining unit which is used for obtaining a normal stomach intestine tissue section image and a pathological section image of a diagnosed gastrointestinal stromal tumor case as the input image data; an image data marking unit which is used for marking the inputted image data; an image database construction unit which is used for carrying out the classification and arrangement of the marked image data provided by the image data marking unit, and constructing a pathological image database; a CNN (convolution neural network) construction unit which is used for constructing a first CNN model; and a CNN model training unit which is used for obtaining an ideal CNN model. According to the invention, the system and method can achieve the precise and high-efficiency intelligent reading of a film, so as to assist the pathological diagnosis of the gastrointestinal stromal tumor clinically, thereby improving the accuracy of pathological diagnosis, work efficiency and working persistent state.

Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

The present invention relates to three gene markers that are useful in classifying tumors. The markers are known herein as DOG1 (GenBank GeneID 55107), KIT (GenBank GeneID 3815) and PDGFRA (GenBank GeneID 5156) and can be used alone or in combination to identify subclasses of tumors. The classification methods are exemplified herein using gastrointestinal stromal tumors (GISTs). It is to be understood and will be appreciated that the same markers may be used in the classification of tumors other than GISTs. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. Classifying may include stratifying the tumor (and thus stratifying a subject having the tumor), e.g., for a clinical trial. The methods may further comprise selecting a treatment based on the classifying step.

The invention discloses a deep learning-based intelligent detection method for nuclear division images in gastrointestinal stromal tumor. The method comprises the following steps: preprocessing an obtained hematoxylin-eosin staining pathological image; taking EfficientDet-D0 as a deep learning detection model, and carrying out training; using U-Net as a deep learning segmentation model, and training the deep learning segmentation model; constructing a deep learning classification model; training the deep learning classification model; detecting the hematoxylin-eosin staining pathological imageof the testee by using the trained deep learning detection model; segmenting the pathological image by using a deep learning segmentation model, and detecting the segmented result; and comparing thenuclear division images detection result based on the deep learning detection model with the nuclear division images detection result based on the deep learning segmentation model to obtain a final classification result. According to the invention, the input hematoxylin-eosin staining image is analyzed, and the number of nuclear division images is detected, so that the judgment on the risk degreeof gastrointestinal stromal tumor is realized.

The invention relates to application of a DLK1 (delta drosophila homolog-like1) gene in preparation of a gastrointestinal stromal tumor diagnostic reagent. The new discovery of the invention can be applied to development of drugs or kits based on RT-PCR, PCR, immunodetection, in-situ hybridization, gene chip and other technologies for diagnosis of gastrointestinal stromal tumors. The invention puts forward for the first time that detection based on DLK1 gene and its products in serum / tissue can be utilized to achieve early diagnosis of GIST or carry out prognosis on GIST patients undergoing surgical treatment, the high-throughput chip screening + real-time quantitative PCR validation established on the gene level and large sample clinical sample validation on the protein level have reliable result, and DLK1 can significantly distinguish tumors and nontumors, high-risk tumors and low-risk tumors both on the gene level and protein level, and the result repeatability is good. Thus, DLK1 gene has good clinical application value.

The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and solvates thereof which have kinase inhibitor activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating and preventing a Bcr-Abl, c-Kit or PDGF-R mediated disorder for which one or more kinase inhibitor is indicated, including neoplasia such as chronic myelogenous leukemia or gastrointestinal stromal tumors. The present invention also provides for processes of making the compounds of Formula I, including salts and solvates thereof, and pharmaceutical compositions comprising the same.

The present invention is directed to a nanoparticulate compositions of imatinib mesylate, or a salt or derivative thereof, having improved pharmacokinetic profiles and reduced fed / fasted variability. The nanoparticulate imatinib mesylate particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors and related diseases.

The invention discloses an application of phellinus igniarius serving as a drug in treatment of tumors. The prepared drug has a good curative effect on such tumors as liver cancer, lung cancer, bladder cancer, colon cancer, cervical cancer, breast cancer, leukemia, lymphoma, osteosarcoma, prostate cancer and gastrointestinal stromal tumor, and not only provides theoretical foundation for the application of the phellinus igniarius in preparation of antitumor drugs and the clinical application thereof, but also has important significance on the comprehensive utilization and industrial development of phellinus igniarius resources, and has important economic benefits and social benefits.

The invention relates to substituted tetrahydronaphthalene amide compound as shown in a general formula I (in the Specification), pharmaceutically acceptable salt thereof, and a preparation method and application. The substituted tetrahydronaphthalene amide compound can be used as an antitumor drug, the invention also provides a preparation method of compounds similar to the substituted tetrahydronaphthalene amide compound and pharmaceutical compositions containing the compounds, and in vitro and in vivo anti-tumor effect research results and acute toxicity research results. The substituted benzo-cyclic amide compound as the antitumor drug, has better antitumor activity and safety, particularly resists imatinib mesylate resistance tumors, can be applied to curing tumors, such as leukemia, gastrointestinal stromal tumor, lung cancer, colon cancer, ovarian cancer and kidney cancer, is wide in therapeutic window, and as antitumor agent, the compound has high application value in the field of medicine.

The invention relates to substituted-indanyl amide-type compounds as shown in the general formula I, pharmaceutically acceptable salt of the compounds and a preparation method and an application thereof. The invention also provides a pharmaceutical composition of the compounds. Through in vitro and in vivo anti-tumor effect research results and acute toxicity research results, the anti-tumor drug substituted-indanyl amide-type compounds have more excellent antitumor activity and safety, especially resisting imatinib drug-resistant tumors, and can be applied in curing tumors such as leukemia, gastrointestinal stromal tumor, lung cancer, colon cancer, ovarian cancer, kidney cancer and the like. Thus, the compounds have wide therapeutic window and have application value when used as an anti-tumor agent in the field of medicine.

The invention is a method of tumorology, imaging, and computer -assisted medicine, involving a method of building a model of malignant potential classification models based on radiological gastric and intestinal tumor.The construction method described in the present invention includes: data collection: abdominal enhancement phase of thin -layer CT image collection; extracting radiation group characteristics; statistical analysis; feature selection and radiation group characteristics model construction; radiology feature model verification and calibration.The method built by the method described by the present invention can classify the vicious potential classification model of gastrointestinal gastrointestinal tumor tumor tumor, which can accurately classify the GIST with different malignant potential, which is a non -invasive technology without increasing the additional cost of patients. Operations operation. Operations.Simple, convenient for clinical promotion.

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, R1, X and Y are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis / mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer / T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.

The present invention discloses an application of a MLH1 gene, and a kit for detecting a gastrointestinal stromal tumor, wherein the kit comprises MLH1 gene sequencing primers. According to the present invention, the inventor finds that: the gastrointestinal stromal tumor is caused by the common KIT and PDGFRA gene mutations, and the MLH1 (V384D) mutation is one of the causes of the gastrointestinal stromal tumor, such that the kit for detecting the gastrointestinal stromal tumor can be provided for rapidly and accurately detecting the MLH1 mutation site of the gastrointestinal stromal tumor and assistedly diagnosing the gastrointestinal stromal tumor so as to assistedly treat the gastrointestinal stromal tumor based on the finding; and after the MLH1 (V384D) mutation is detected by using the kit, the gene targeting drug can be adopted to specifically treat patients, such that the use of the targeting drug is specific.

The invention discloses a construction method and an application of gastrointestinal stromal tumor polygenic variation library. In the method, monotube is performed to a plurality of target sequences, so that target area capturing before the construction of the library is quickly completed, wherein the whole target area capturing process only needs 2-3 h, manual time being only 15-30 min. With combination of a high-throughput sequencing platform and other library construction universal kits, the method solves a difficult that detection on multiple genes and target points is required in clinical treatment of the gastrointestinal stromal tumor on the basis of a less quantity of clinical samples at present. The method is low in cost and can be applied in various high-throughput sequencing platforms, gene chip platforms and hybridization detection platforms in the prior art.

The invention belongs to the technical field of medical artificial intelligence, and discloses an ultrasonic endoscope, an artificial intelligence auxiliary identification method and system, a terminal and a medium, and the method comprises the steps: obtaining the image data of an ultrasonic endoscope video or a static image in an ultrasonic endoscope monitor in real time through an image collection module, and intercepting an image frame; segmenting and extracting the tumor part image based on the acquired image by adopting artificial image segmentation or utilizing a deep learning segmentation model through an image segmentation module; unifying the sizes of the segmented images through an image conversion module, and carrying out normalization processing to obtain a modularized picture, namely a standardized lesion part image; dividing the modular picture into an interstitial tumor image or a smooth myoma image by using a deep learning classification model through an image classification module; and outputting an image classification result through an output module. According to the method provided by the invention, the image identification accuracy can be effectively improved, and misdiagnosis is reduced.

The invention belongs to the fields such as oncology, iconography and machine learning, and relates to a construction method of a gastrointestinal stromal tumor malignant potential classification model based on a support vector machine. The construction method according to the invention comprises the steps of data acquisition, namely performing thin-layer CT image acquisition in a belly reinforcing period; extracting and screening a characteristic; obtaining a punishment parameter and a kernel function parameter through cross validation; establishing a classification model through the parameters; and checking model classification performance. The classification model which is constructed according to the method and is based on the support vector machine can accurately classify the gastrointestinal stromal tumor to two kinds, namely a low malignant potential kind and a high malignant potential kind. Furthermore the classification model is based on an existing image resource and does not cause an additional cost of a patient, thereby facilitating clinical popularization.

The invention discloses a monoclonal antibody for mouse anti-human type BRAF V600E mutant protein. The monoclonal antibody is high in specificity, stable in expression and high in potency, can be applied to BRAF V600E mutant protein in malignant tumors, and has a certain medicine-based research value. The invention also relates to application of the monoclonal antibody to preparation of an immunohistochemical detecting tool for detecting the BRAF V600E mutant protein. According to the monoclonal antibody and the application of the monoclonal antibody disclosed by the invention, an immunohistochemical technology based on the BRAF V600E monoclonal antibody is built and is used in auxiliary diagnosis, selection of treatment schemes and prognosis of the malignant tumors, wherein the malignanttumors mainly comprise malignant melanoma, lung adenocarcinoma, colorectal carcinoma, gastrointestinal stromal tumors, papillary thyroid carcinoma, astrocytoma, hairy cell leukemia, lynch syndrome andthe like. Based on simple operation and less charging of the immunohistochemical method, the method can be used as a first-choice detection method of BRAF V600E gene mutation in clinic work.

The invention relates to a purpose of a medicine which is prepared by triptolide and is used for curing tumor that is relevant to c-KIT tyrosine kinase. The invention verifies that a micromolecule natural product triptolide (TPL) can down-regulate the protein expression of D816V point mutation c-KIT for the first time, inhibit the phosphorylation thereof and induce the cell apoptosis of STI571 resistance c-KIT point mutation (D816). The invention discloses a novel micromolecule stayer of tyrosine kinase, more particularly overcomes the problem that the resistance property of the medicine STI 571 can be inhibited by the first-line tyrosine kinase that is used on the clinic at present. The TPL can be used for developing a novel specific medicine for curing tumors being relevant to c-KIT mutation, such as gastrointestinal stromal tumor, systemic mastocytosis and small cell lung cancer, etc.

The invention provides application of a DKK4 gene and a coding protein thereof in preparation of a medicament, in particular application in preparation of a medicament for detecting or treating a gastrointestinal stromal tumor (GIST). The medicament is a detection medicament consisting of a DKK4 antibody serving as an active ingredient and a medicinal carrier or consisting of a DKK4 specific primer serving as an active ingredient and a medicinal carrier. The medicament is a detection kit prepared from the DKK4 antibody or the specific primer thereof serving as the active ingredient and a medicinal carrier. Early diagnosis of the GIST or prognosis of a GIST patient accepting operative treatment is realized by using the detection based on the DKK gene and the product thereof in serum / tissues; through high-flux chip screening established on the gene level, real-time quantitative polymerase chain reaction (PCR) verification and large clinical sample verification on the protein level, the results are reliable; according to the experimental results, the DKK4 can remarkably distinguish tumor and non-tumor, high-risk tumor and low-risk tumor on both the gene level and the protein level, and the repeatability of the results is high; and the difference of the expression quantity of the DKK4 gene between different groups is huge, and the DKK4 gene has a good clinical application value.